Fewer Prevnar jabs just as effective

A new study demonstrates that three doses of Wyeth's pneumococcal vaccine Prevnar works as well as the four-dose regimen currently in use. And a reduction in jabs could save payers a significant amount of money. "In my opinion you could safely go to two-plus-one," Elisabeth Sanders, one of the study's co-authors, told Dow Jones. "Why not save the one injection if it's not required?" Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.